ArticleCancers2026
GAS5 Downregulation Promotes the Progression of Triple-Negative Breast Cancer by Regulating Tumor Cells-MDSCs Crosstalk.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTriple-negative breast cancer (TNBC) is exceptionally aggressive, with a high recurrence rate, resistance to chemotherapy, and a tendency to metastasize. The long non-coding RNA growth arrest-specific 5 (GAS5) is associated with TNBC progression; however, the specific mechanism still requires further exploration.
methodsIntegrative bioinformatics analyses and qRT-PCR were used to investigate the significant downregulation of GAS5 in TNBC cells and tissues. The functional role and molecular mechanism of GAS5 in inhibiting the progression of TNBC and increasing sensitivity to chemotherapy were investigated using in vitro experiments, including qPCR, Western blot, CCK8 assay, Transwell, Chemotaxis assays, RNA immunoprecipitation, m6A-RNA immunoprecipitation, Chromatin immunoprecipitation, Flow cytometry, ELISA, and Luciferase reporter assays, and in vivo experiments using tumor xenografts.
resultsGAS5 was significantly downregulated in TNBC cells and tissues, as well as in chemotherapy-resistant conditions. Functional assays revealed that overexpression of GAS5 attenuated the progression of TNBC and increased their sensitivity to docetaxel (DTX) both in vitro and in vivo. Furthermore, we confirmed that GAS5 recruited YTHDF2 to target MYBL2, which in turn downregulated the chemokine CCL2, which reduced the recruitment of myeloid-derived immunosuppressive cells (MDSCs). In addition, IL-6 from MDSCs downregulated GAS5 to promote TNBC growth and attenuate the sensitivity of TNBC to DTX through the STAT3/UPF1 axis, forming a feedback loop between tumor cells and MDSCs.
conclusionsThese findings illustrated the significance of the GAS5-mediated mutual regulatory pathway between tumor cells and MDSCs in TNBC and provide new avenues for the development of targeted therapies in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.